Tom and All,
Isn't the following PRN nr excellent news...haven't we been waiting and waiting for this validation??? so, why not some kind of positive reaction from the stock???
CEL-SCI Corporation Announces Issuance of Key U.S. Patent on Vaccine Technology
07/31 06:44
<<<VIENNA, Va., July 31 /PRNewswire/ -- CEL-SCI Corporation (Amex: CVM) announced today the issuance of a key U.S. patent expanding the coverage on CEL-SCI's L.E.A.P.S.™ (Ligand Epitope Antigen Presentation System) vaccine technology. The patent, number 6,096,315, is entitled "Heterofunctional Cellular Immunological Reagents, Vaccines Containing Same and Methods for the Use of Same."
Geert Kersten, Chief Executive Officer of CEL-SCI Corporation said, "The filing date of this patent, 1988, precedes the filing date for patents which have already issued to other groups in the field of T-cell immunology. This priority date may make this patent very important to us in the future."
Dr. Dan Zimmerman, Senior Vice President Research, Cellular Immunology of CEL-SCI, and inventor of the technology said, "the L.E.A.P.S. technology allows for the preparation of designer vaccines that can target specific types of immune cells and elicit the most appropriate responses (cellular or humoral) for that disease. This allows us to utilize protective epitopes from bacterial, viral or cancer proteins, or genes and avoid the use of harmful or non-relevant epitopes (suppressor, autoimmune or dominant)."
L.E.A.P.S. is currently being evaluated in eight collaborations: National Cancer Institute (both cancer and HIV), Max-Delbruck Center for Molecular Medicine, Berlin (cancer), Johns Hopkins University (heart disease), University of Maryland (TB), University of Nebraska Medical Center (HIV), U.S. Naval Medical Research Center (malaria), and Northeastern Ohio Universities College of Medicine (herpes simplex).
L.E.A.P.S. is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. L.E.A.P.S. compounds ("constructs") consist of a peptide epitope associated with a disease-causing agent linked to a T-cell binding peptide ligand (TCBL). Together they induce the immune system to mount either a cellular (e.g., T-cell), humoral (antibody) or a mixed immune response as a means to treat, control or prevent disease. Therefore, L.E.A.P.S. is thought to be a delivery vehicle that directs or controls the immune response to the desired outcome. This ability to preferentially direct the immune system is a major breakthrough. Any diseases for which antigenic epitope sequences have been identified, such as infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, are potential candidates for this technology. More information on L.E.A.P.S. is available at cel-sci.com.
CEL-SCI Corporation is a biopharmaceutical company whose mission is to identify, develop and commercialize products which stimulate the immune system to combat disease. Its most advanced product is Multikine™, an immunomodulator currently in several clinical trials for head & neck and prostate cancer.
"CEL-SCI press releases are available through Company News On-Call by fax, 800-758-5804, Ext. 445563, or at cel-sci.com on the Internet."
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinic results demonstrated in preclinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 1999. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.>>> |
